Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2342728 | 0.98 | HPGD (0.42) | ALDH1A1AKR1C3HPGDBRD9CYP1A2 | |
| SCHEMBL2337506 | 0.95 | ALDH1A1 (0.46) | ALDH1A1AKR1C3HPGDCYP1A2CYP3A4 | |
| SCHEMBL2347313 | 0.80 | ALDH1A1 (0.38) | ALDH1A1HPGD | |
| SCHEMBL2350173 | 0.80 | HPGD (0.38) | AKR1C3HPGDGAA | |
| SCHEMBL182890 | 0.78 | ALDH1A1 (0.51) | ALDH1A1AKR1C3HPGDBRD9CYP1A2 | |
| SCHEMBL23387936 | 0.75 | MEN1 (0.31) | ALDH1A1 | |
| SCHEMBL2342841 | 0.75 | SLC6A2 (0.40) | HPGD | |
| SCHEMBL16570287 | 0.75 | SLC6A2 (0.40) | — | |
| SCHEMBL2344200 | 0.75 | PTGS2 (0.44) | — | |
| SCHEMBL255160 | 0.74 | AKR1C3 (0.51) | ALDH1A1AKR1C3HPGDBRD9HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115003663-B | Novel heteroaryl-triazole compounds as pesticides | 拜耳公司 | 2024-04-30 | — | — | CN | claimed |
| US-20230058623-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-02-23 | — | — | US | claimed |
| CN-115003663-A | Novel heteroaryl-triazole compounds as pesticides | 拜耳公司 | 2022-09-02 | — | — | CN | claimed |
| WO-2021099303-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-27 | — | — | WO | claimed |
| CN-115003663-B | Novel heteroaryl-triazole compounds as pesticides | 拜耳公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20230058623-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | ELANCO ANIMAL HEALTH GMBH (DE) | 2023-02-23 | — | — | US | disclosed |
| CN-115003663-A | Novel heteroaryl-triazole compounds as pesticides | 拜耳公司 | 2022-09-02 | — | — | CN | disclosed |
| WO-2021099303-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-27 | — | — | WO | disclosed |
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-2361902-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230467-A1 | 4,6-DIAMINONICOTINAMIDE COMPOUND | JAK3, JAK2, JAK1 | ALDH1A1 1378/4885AKR1C3 2605/4885HPGD 2840/4885 |
| US-20230058623-A1 | NOVEL HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES | PRXL2A, GLRX3, CYP4F3 | ALDH1A1 4213/4885AKR1C3 894/4885HPGD 4450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.